Authors: Kerbusch, T Herben, VMM Jeuken, MJJ Ouwerkerk, J Keizer, HJ Beijnen, JH

Citation: T. Kerbusch et al., Distribution of ifosfamide and metabolites between plasma and erythrocytes, BIOPHARM DR, 22(3), 2001, pp. 99-108

Authors: Herben, VMM Schellens, JHM Swart, M Gruia, G Vernillet, L Beijnen, JH Huinink, WWT

Citation: Vmm. Herben et al., Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors, J CL ONCOL, 17(6), 1999, pp. 1897-1905

Authors: Herben, VMM van Gijn, R Schellens, JHM Schot, M Lieverst, J Hillebrand, MJX Schoemaker, NE Porro, MG Beijnen, JH Huinink, WWT

Citation: Vmm. Herben et al., Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulationin patients with advanced solid tumors, J CL ONCOL, 17(6), 1999, pp. 1906-1914

Authors: Herben, VMM Panday, VRN Richel, DJ Schellens, JHM van der Vange, N Rosing, H Beusenberg, FD Hearn, S Doyle, E Beijnen, JH Huinink, WWT

Citation: Vmm. Herben et al., Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 747-755

Authors: Tuk, B Van Oostenbruggen, MF Herben, VMM Mandema, JW Danhof, M

Citation: B. Tuk et al., Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: Midazolam and alpha-OH-midazolam, J PHARM EXP, 289(2), 1999, pp. 1067-1074

Authors: Herben, VMM Rosing, H Huinink, WWT van Zomeren, DM Batchelor, D Doyle, E Beusenberg, FD Beijnen, JH Schellens, JHM

Citation: Vmm. Herben et al., Oral topotecan: bioavailability and effect of food co-administration, BR J CANC, 80(9), 1999, pp. 1380-1386